Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pediatric Hematology/Oncology
•
BRAF+
•
Langerhans Cell Histiocytosis
Do you recommend using cell-free BRAFV600E to track response to therapy in pediatric patients with langerhans cell histiocytosis?
Related Questions
How would you approach secondary stroke prevention in an adult with Hemoglobin SC disease?
How would you manage a young, HIV-negative patient with good performance status with primary refractory Burkitt Lymphoma involving the CNS and systemic disease?
Can anti-cardiolipin or anti-beta-2 glycoprotein antibodies cause prolonged PTT in the absence of a lupus anticoagulant?
How do you counsel sickle cell patients on the use of G-CSF to treat neutropenia from other causes, like malignancy?
Is there any benefit of using aspirin to mitigate VTE risk in testosterone-induced polycythemia?
What was the rationale behind using RANO-HGG criteria instead of RAPNO criteria for the primary endpoint in the FIREFLY-1 trial for pLGG?
How would you manage a young patient with HL who develops HF (EF < 30%) after 4 cycles of A+AVD who obtained a PET2 CR?
Does the preferred regimen for advanced stage Nodular lymphocyte predominant Hodgkin lymphoma differ in pediatrics from adult treatment?
What are the treatment options for relapsed T-ALL in a patient who was nonadherent with AALL and hyper-CVAD regimens?
How quickly do you expect iron stores to decrease after starting iron chelators?
